BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 29316610)

  • 1. Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies.
    Schmohl JU; Todhunter D; Taras E; Bachanova V; Vallera DA
    Toxins (Basel); 2018 Jan; 10(1):. PubMed ID: 29316610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma.
    Vallera DA; Todhunter DA; Kuroki DW; Shu Y; Sicheneder A; Chen H
    Clin Cancer Res; 2005 May; 11(10):3879-88. PubMed ID: 15897589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies.
    Bachanova V; Frankel AE; Cao Q; Lewis D; Grzywacz B; Verneris MR; Ustun C; Lazaryan A; McClune B; Warlick ED; Kantarjian H; Weisdorf DJ; Miller JS; Vallera DA
    Clin Cancer Res; 2015 Mar; 21(6):1267-72. PubMed ID: 25770294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases.
    Vallera DA; Oh S; Chen H; Shu Y; Frankel AE
    Mol Cancer Ther; 2010 Jun; 9(6):1872-83. PubMed ID: 20530709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity.
    Du X; Beers R; Fitzgerald DJ; Pastan I
    Cancer Res; 2008 Aug; 68(15):6300-5. PubMed ID: 18676854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-βII depletion.
    Biberacher V; Decker T; Oelsner M; Wagner M; Bogner C; Schmidt B; Kreitman RJ; Peschel C; Pastan I; Meyer Zum Büschenfelde C; Ringshausen I
    Haematologica; 2012 May; 97(5):771-9. PubMed ID: 22180432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutagenic Deimmunization of Diphtheria Toxin for Use in Biologic Drug Development.
    Schmohl JU; Todhunter D; Oh S; Vallera DA
    Toxins (Basel); 2015 Oct; 7(10):4067-82. PubMed ID: 26473923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diphtheria toxin-based anti-human CD19 immunotoxin for targeting human CD19
    Zheng Q; Wang Z; Zhang H; Huang Q; Madsen JC; Sachs DH; Huang CA; Wang Z
    Mol Oncol; 2017 May; 11(5):584-594. PubMed ID: 28306193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma.
    Takeshita A; Shinjo K; Yamakage N; Ono T; Hirano I; Matsui H; Shigeno K; Nakamura S; Tobita T; Maekawa M; Ohnishi K; Sugimoto Y; Kiyoi H; Naoe T; Ohno R
    Br J Haematol; 2009 Jun; 146(1):34-43. PubMed ID: 19388933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel synergizes with exposure time adjusted CD22-targeting immunotoxins against B-cell malignancies.
    Müller F; Stookey S; Cunningham T; Pastan I
    Oncotarget; 2017 May; 8(19):30644-30655. PubMed ID: 28423727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant immunotoxins for treating cancer.
    FitzGerald DJ; Kreitman R; Wilson W; Squires D; Pastan I
    Int J Med Microbiol; 2004 Apr; 293(7-8):577-82. PubMed ID: 15149034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.
    Lopes de Menezes DE; Pilarski LM; Allen TM
    Cancer Res; 1998 Aug; 58(15):3320-30. PubMed ID: 9699662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two Saporin-Containing Immunotoxins Specific for CD20 and CD22 Show Different Behavior in Killing Lymphoma Cells.
    Polito L; Mercatelli D; Bortolotti M; Maiello S; Djemil A; Battelli MG; Bolognesi A
    Toxins (Basel); 2017 May; 9(6):. PubMed ID: 28556822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies.
    Bera TK; Onda M; Kreitman RJ; Pastan I
    Leuk Res; 2014 Oct; 38(10):1224-9. PubMed ID: 25127689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diphtheria-toxin based anti-human CCR4 immunotoxin for targeting human CCR4(+) cells in vivo.
    Wang Z; Wei M; Zhang H; Chen H; Germana S; Huang CA; Madsen JC; Sachs DH; Wang Z
    Mol Oncol; 2015 Aug; 9(7):1458-70. PubMed ID: 25958791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia, and B-cell non-Hodgkin lymphoma as a target of immunotoxins.
    Du X; Nagata S; Ise T; Stetler-Stevenson M; Pastan I
    Blood; 2008 Jan; 111(1):338-43. PubMed ID: 17895404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor D-1-methyl-tryptophan.
    Zhang X; Yang Y; Zhang L; Lu Y; Zhang Q; Fan D; Zhang Y; Zhang Y; Ye Z; Xiong D
    J Hematol Oncol; 2017 Feb; 10(1):56. PubMed ID: 28228105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing.
    Bonardi MA; French RR; Amlot P; Gromo G; Modena D; Glennie MJ
    Cancer Res; 1993 Jul; 53(13):3015-21. PubMed ID: 7686448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy.
    Vallera DA; Chen H; Sicheneder AR; Panoskaltsis-Mortari A; Taras EP
    Leuk Res; 2009 Sep; 33(9):1233-42. PubMed ID: 19327829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.